Phibro Animal Health Corporation experienced strong growth in 2025, with net sales surging 39% in Q4 to $378.7 million, driven by a 53% increase in the Animal Health segment. The company’s stock is up over 80% year-to-date, fueled by the successful acquisition of Zoetis’ MFA portfolio. Analysts are optimistic about continued growth, with earnings forecasts raised for fiscal 2025 and 2026.

Phibro Animal Health Corporation is projecting $1.43 to $1.48 billion in revenue and $225–$235 million in adjusted EBITDA for fiscal 2026, reflecting confidence in its trajectory. While PAHC shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk.

Analysts have raised earnings forecasts for Phibro Animal Health Corporation, reflecting optimism around continued growth. The company’s recent momentum has been driven by the successful acquisition of Zoetis’ MFA portfolio, with significant improvements in net income and adjusted EBITDA.

Phibro Animal Health Corporation’s stock has soared more than 80% year-to-date in 2025, outperforming peers and the broader market. The company is expanding in the companion animal market and experiencing global adoption of OmniGen-AF, a nutritional supplement for the dairy industry.

Investor confidence in Phibro Animal Health Corporation has been strong, with the stock up over 80% year-to-date in 2025. The company’s recent growth is attributed to expanded product lines and rising global demand, serving both food and companion animals across 90 countries.

Read more at Yahoo Finance: Phibro Animal Health Corporation (PAHC) Soars 39% in Q4, Stock Up 80% YTD on Zoetis Acquisition Boost